Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 1, 1999, Pages 149-151

  Cuenca Estrella, Manuel ^a   Ruiz Díez, Beatriz ^a   Martínez Suárez, Joaquín V ^a   Monzón, Araceli ^a   Rodríguez Tudela, Juan L ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; CONTROLLED STUDY; NONHUMAN; SCEDOSPORIUM AIOSPERMUM; SCEDOSPORIUM PROLIFICANS;

ANTIFUNGAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDALLESCHERIA; PYRIMIDINES; SPAIN; TRIAZOLES;

EID: 0344572680     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.1.149     Document Type: Article

References (10)

1. Rippon, J. W. (1988). Pseudallescheriasis. In Medical Mycology: the Pathogenic Fungi and the Pathogenic Actinomycetes, 3rd edn (Rippon, J. W., Ed.), pp. 651-80. W. B. Saunders, Philadelphia, PA.
2. de Hoog, G. S., Marvin-Sikkema, F. D., Lahpoor, G. A., Gottschall, J. C., Prins, R. A. & Gueho, E. (1994). Ecology and physiology of the emerging opportunistic fungi Pseudoallescheria boydii and Scedosporium prolificans. Mycoses 37, 71-5.
3. Berenguer, J., Rodríguez-Tudela, J. L., Richard, C., Alvarez, M., Sanz, M. A., Guztelurrutia, L. et al. and the Scedosporium prolificans Spanish Study Group. (1997). Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Medicine 76, 256-65.
4. Radford, S. A., Johnson, E. M. & Warnock, D. W. (1997). In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrobial Agents and Chemotherapy 41, 841-3.
5. Schwartz, S., Milatovic, D. & Thiel, E. (1997). Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. British Journal of Haematology 97, 663-5.
6. National Committee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard Document M27-A. NCCLS, Villanova, PA.
7. Rodríguez-Tudela, J. L. & Martínez-Suárez, J. V. (1994). Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrobial Agents and Chemotherapy 38, 45-8.
8. Nomdedéu, J., Brunet, S., Martino, R., Altés, A., Ausina, V. & Domingo-Albös, A. (1993). Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report. Clinical Infectious Diseases 16, 731-3.
9. De Beule, K. (1996). Itraconazole: pharmacology, clinical experience and future development. International Journal of Antimicrobial Agents 6, 175-81.
10. Martin, M. V., Yates, J. & Hitchcock, C. A. (1997). Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrobial Agents and Chemotherapy 41, 13-6.